Since 1926 Guerbet Group has had a long-standing tradition as a pioneer in the research and development of medical imaging contrast media. Headquartered in Villepinte, France, Guerbet is a publicly traded company with market share in Europe of more than 25% and 8% worldwide for contrast media.
Guerbet Group is committed to deploying its know-how and innovative capacity to meet the major public health challenges of the 21st century.
Its Mission is to contribute to advances in the diagnosis of major pathologies (cardiovascular diseases, cancer, inflammatory and neurodegenerative diseases) by proposing innovative and effective imaging solutions for improved patient management throughout the world.
Guerbet Group's goal is to pursue sustainable growth in the years ahead by meeting needs resulting from demographic trends, medical progress and public health challenges.